H.C. Wainwright lowered the firm’s price target on Zentalis to $40 from $46 and keeps a Buy rating on the shares. The firm revised spending and launch assumptions for each of the company’s programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
- Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zentalis Pharmaceuticals Announces Executive Financial Transition
- Zentalis Pharmaceuticals to Present at Upcoming Conferences
- Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024